Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS

OBJECTIVE: To assess the safety, tolerability, and preliminary efficacy of NP001, a novel immune regulator of inflammatory monocytes/macrophages, for slowing progression of amyotrophic lateral sclerosis (ALS). METHODS: This was a phase 2 randomized, double-blind, placebo-controlled trial of NP001 in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Neuroimmunol Neuroinflamm
Main Authors: Miller, Robert G., Block, Gilbert, Katz, Jonathan S., Barohn, Richard J., Gopalakrishnan, Vidhya, Cudkowicz, Merit, Zhang, Jane R., McGrath, Michael S., Ludington, Elizabeth, Appel, Stan H., Azhir, Ari
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396529/
https://ncbi.nlm.nih.gov/pubmed/25884010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados